PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
21424700-0	2012	Growth inhibition induced by antiprogestins RU-38486, ORG-31710, and CDB-2914 in ovarian cancer cells involves inhibition of cyclin dependent kinase 2.	cdb	69-72	cyclin dependent kinase 2	Homo sapiens	125-150
24629709-10	2014	CDB detachment retained surface chemokine receptor expression and consequently increased migration to CCL22, CXCL12 and CCL4, in contrast with TrypLE-detached MSC.	cdb	0-3	C-X-C motif chemokine receptor 4	Homo sapiens	32-50
24629709-10	2014	CDB detachment retained surface chemokine receptor expression and consequently increased migration to CCL22, CXCL12 and CCL4, in contrast with TrypLE-detached MSC.	cdb	0-3	C-C motif chemokine ligand 22	Homo sapiens	102-107
24629709-10	2014	CDB detachment retained surface chemokine receptor expression and consequently increased migration to CCL22, CXCL12 and CCL4, in contrast with TrypLE-detached MSC.	cdb	0-3	C-X-C motif chemokine ligand 12	Homo sapiens	109-115
24629709-10	2014	CDB detachment retained surface chemokine receptor expression and consequently increased migration to CCL22, CXCL12 and CCL4, in contrast with TrypLE-detached MSC.	cdb	0-3	C-C motif chemokine ligand 4	Homo sapiens	120-124
23718875-12	2013	Continuous co-incubation with CDB and ARG increased NO2-/NO3-, glucose uptake, GLUT-1, AMPK expression and activity, and maintained overall cellular glucose, O2 - and ONOO- to control conditions.	cdb	30-33	solute carrier family 2 member 1	Homo sapiens	79-85
23718875-12	2013	Continuous co-incubation with CDB and ARG increased NO2-/NO3-, glucose uptake, GLUT-1, AMPK expression and activity, and maintained overall cellular glucose, O2 - and ONOO- to control conditions.	cdb	30-33	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	87-91
23710985-6	2013	P16 expression in the specimen from CDB was independently evaluated using immunohistochemistry in all patients.	cdb	36-39	cyclin dependent kinase inhibitor 2A	Homo sapiens	0-3
23710985-12	2013	CONCLUSION: In our study of 122 patients with CDB we found that in group of CIN 1 patients, p16 evaluation had significant predictive value for final histology.	cdb	46-49	cyclin dependent kinase inhibitor 2A	Homo sapiens	92-95
20881264-0	2010	Indian Hedgehog and its targets in human endometrium: menstrual cycle expression and response to CDB-2914.	cdb	97-100	Indian hedgehog signaling molecule	Homo sapiens	0-15
20881264-6	2010	RESULTS: RT-PCR showed expression of IHH, SMO, PTCH1, GLI1, and GLI2, with significant increases in IHH (5.2-fold) and GLI1 (3.6-fold) in endometrium exposed to CDB-2914 compared with placebo.	cdb	161-164	Indian hedgehog signaling molecule	Homo sapiens	37-40
20881264-9	2010	Compared with follicular-phase controls, women exposed to CDB-2914 showed increased IHH expression in all compartments except stromal cytoplasm (P=0.0199-0.0423); GLI1 was up-regulated in glandular nuclei and cytoplasm compared with both volunteers and women receiving placebo (P<=0.0416).	cdb	58-61	Indian hedgehog signaling molecule	Homo sapiens	84-87
20881264-9	2010	Compared with follicular-phase controls, women exposed to CDB-2914 showed increased IHH expression in all compartments except stromal cytoplasm (P=0.0199-0.0423); GLI1 was up-regulated in glandular nuclei and cytoplasm compared with both volunteers and women receiving placebo (P<=0.0416).	cdb	58-61	GLI family zinc finger 1	Homo sapiens	163-167
20933117-11	2010	CDB-2914 increased ECM metalloproteinase inducer, matrix metalloproteinase (MMP)-1, MMP-8 contents and decreased tissue inhibitors of MMP (TIMP)-1, TIMP-2 contents as well as type I and type III collagen contents in cultured leiomyoma cells, without comparable effects on cultured normal myometrial cells.	cdb	0-3	matrix metallopeptidase 1	Homo sapiens	50-82
20933117-11	2010	CDB-2914 increased ECM metalloproteinase inducer, matrix metalloproteinase (MMP)-1, MMP-8 contents and decreased tissue inhibitors of MMP (TIMP)-1, TIMP-2 contents as well as type I and type III collagen contents in cultured leiomyoma cells, without comparable effects on cultured normal myometrial cells.	cdb	0-3	matrix metallopeptidase 8	Homo sapiens	84-89
20933117-11	2010	CDB-2914 increased ECM metalloproteinase inducer, matrix metalloproteinase (MMP)-1, MMP-8 contents and decreased tissue inhibitors of MMP (TIMP)-1, TIMP-2 contents as well as type I and type III collagen contents in cultured leiomyoma cells, without comparable effects on cultured normal myometrial cells.	cdb	0-3	TIMP metallopeptidase inhibitor 1	Homo sapiens	113-146
20933117-11	2010	CDB-2914 increased ECM metalloproteinase inducer, matrix metalloproteinase (MMP)-1, MMP-8 contents and decreased tissue inhibitors of MMP (TIMP)-1, TIMP-2 contents as well as type I and type III collagen contents in cultured leiomyoma cells, without comparable effects on cultured normal myometrial cells.	cdb	0-3	TIMP metallopeptidase inhibitor 2	Homo sapiens	148-154
15572421-0	2005	Progesterone receptor modulator CDB-2914 down-regulates proliferative cell nuclear antigen and Bcl-2 protein expression and up-regulates caspase-3 and poly(adenosine 5"-diphosphate-ribose) polymerase expression in cultured human uterine leiomyoma cells.	cdb	32-35	BCL2 apoptosis regulator	Homo sapiens	95-100
18216291-4	2008	In cultured leiomyoma cells, CDB-2914 treatment at concentrations greater than or equal to 10(-8) M significantly increased EMMPRIN, MMP-1 and MMP-8 protein contents and MMP-1, MMP-2, MMP-3 and MMP-9 mRNA levels, and activity of MMP-1, MMP-2, MMP-3 and MMP-9 in the medium.	cdb	29-32	basigin (Ok blood group)	Homo sapiens	124-131
18216291-4	2008	In cultured leiomyoma cells, CDB-2914 treatment at concentrations greater than or equal to 10(-8) M significantly increased EMMPRIN, MMP-1 and MMP-8 protein contents and MMP-1, MMP-2, MMP-3 and MMP-9 mRNA levels, and activity of MMP-1, MMP-2, MMP-3 and MMP-9 in the medium.	cdb	29-32	matrix metallopeptidase 1	Homo sapiens	133-138
18216291-4	2008	In cultured leiomyoma cells, CDB-2914 treatment at concentrations greater than or equal to 10(-8) M significantly increased EMMPRIN, MMP-1 and MMP-8 protein contents and MMP-1, MMP-2, MMP-3 and MMP-9 mRNA levels, and activity of MMP-1, MMP-2, MMP-3 and MMP-9 in the medium.	cdb	29-32	matrix metallopeptidase 8	Homo sapiens	143-148
18216291-4	2008	In cultured leiomyoma cells, CDB-2914 treatment at concentrations greater than or equal to 10(-8) M significantly increased EMMPRIN, MMP-1 and MMP-8 protein contents and MMP-1, MMP-2, MMP-3 and MMP-9 mRNA levels, and activity of MMP-1, MMP-2, MMP-3 and MMP-9 in the medium.	cdb	29-32	matrix metallopeptidase 1	Homo sapiens	170-175
18216291-4	2008	In cultured leiomyoma cells, CDB-2914 treatment at concentrations greater than or equal to 10(-8) M significantly increased EMMPRIN, MMP-1 and MMP-8 protein contents and MMP-1, MMP-2, MMP-3 and MMP-9 mRNA levels, and activity of MMP-1, MMP-2, MMP-3 and MMP-9 in the medium.	cdb	29-32	matrix metallopeptidase 2	Homo sapiens	177-182
18216291-4	2008	In cultured leiomyoma cells, CDB-2914 treatment at concentrations greater than or equal to 10(-8) M significantly increased EMMPRIN, MMP-1 and MMP-8 protein contents and MMP-1, MMP-2, MMP-3 and MMP-9 mRNA levels, and activity of MMP-1, MMP-2, MMP-3 and MMP-9 in the medium.	cdb	29-32	matrix metallopeptidase 3	Homo sapiens	184-189
18216291-4	2008	In cultured leiomyoma cells, CDB-2914 treatment at concentrations greater than or equal to 10(-8) M significantly increased EMMPRIN, MMP-1 and MMP-8 protein contents and MMP-1, MMP-2, MMP-3 and MMP-9 mRNA levels, and activity of MMP-1, MMP-2, MMP-3 and MMP-9 in the medium.	cdb	29-32	matrix metallopeptidase 9	Homo sapiens	194-199
18216291-4	2008	In cultured leiomyoma cells, CDB-2914 treatment at concentrations greater than or equal to 10(-8) M significantly increased EMMPRIN, MMP-1 and MMP-8 protein contents and MMP-1, MMP-2, MMP-3 and MMP-9 mRNA levels, and activity of MMP-1, MMP-2, MMP-3 and MMP-9 in the medium.	cdb	29-32	matrix metallopeptidase 1	Homo sapiens	170-175
18216291-4	2008	In cultured leiomyoma cells, CDB-2914 treatment at concentrations greater than or equal to 10(-8) M significantly increased EMMPRIN, MMP-1 and MMP-8 protein contents and MMP-1, MMP-2, MMP-3 and MMP-9 mRNA levels, and activity of MMP-1, MMP-2, MMP-3 and MMP-9 in the medium.	cdb	29-32	matrix metallopeptidase 2	Homo sapiens	236-241
18216291-4	2008	In cultured leiomyoma cells, CDB-2914 treatment at concentrations greater than or equal to 10(-8) M significantly increased EMMPRIN, MMP-1 and MMP-8 protein contents and MMP-1, MMP-2, MMP-3 and MMP-9 mRNA levels, and activity of MMP-1, MMP-2, MMP-3 and MMP-9 in the medium.	cdb	29-32	matrix metallopeptidase 3	Homo sapiens	243-248
18216291-4	2008	In cultured leiomyoma cells, CDB-2914 treatment at concentrations greater than or equal to 10(-8) M significantly increased EMMPRIN, MMP-1 and MMP-8 protein contents and MMP-1, MMP-2, MMP-3 and MMP-9 mRNA levels, and activity of MMP-1, MMP-2, MMP-3 and MMP-9 in the medium.	cdb	29-32	matrix metallopeptidase 9	Homo sapiens	253-258
17980739-17	2007	These findings strongly support the notion that a genetic diagnosis should be determined for CDB and other dystrophies associated with mutations in TGFBI/BIGH3.	cdb	93-96	transforming growth factor beta induced	Homo sapiens	148-153
17980739-17	2007	These findings strongly support the notion that a genetic diagnosis should be determined for CDB and other dystrophies associated with mutations in TGFBI/BIGH3.	cdb	93-96	transforming growth factor beta induced	Homo sapiens	154-159
16720624-0	2006	Progesterone receptor modulator CDB-2914 down-regulates vascular endothelial growth factor, adrenomedullin and their receptors and modulates progesterone receptor content in cultured human uterine leiomyoma cells.	cdb	32-35	progesterone receptor	Homo sapiens	0-21
16720624-0	2006	Progesterone receptor modulator CDB-2914 down-regulates vascular endothelial growth factor, adrenomedullin and their receptors and modulates progesterone receptor content in cultured human uterine leiomyoma cells.	cdb	32-35	vascular endothelial growth factor A	Homo sapiens	56-90
16720624-0	2006	Progesterone receptor modulator CDB-2914 down-regulates vascular endothelial growth factor, adrenomedullin and their receptors and modulates progesterone receptor content in cultured human uterine leiomyoma cells.	cdb	32-35	adrenomedullin	Homo sapiens	92-106
16720624-0	2006	Progesterone receptor modulator CDB-2914 down-regulates vascular endothelial growth factor, adrenomedullin and their receptors and modulates progesterone receptor content in cultured human uterine leiomyoma cells.	cdb	32-35	progesterone receptor	Homo sapiens	141-162
16720624-4	2006	The concomitant treatment with 10(-6) M CDB-2914 significantly decreased the progesterone-induced VEGF-A, VEGF-B and ADM contents in cultured leiomyoma cells but not in normal myometrial cells.	cdb	40-43	vascular endothelial growth factor A	Homo sapiens	98-104
16720624-4	2006	The concomitant treatment with 10(-6) M CDB-2914 significantly decreased the progesterone-induced VEGF-A, VEGF-B and ADM contents in cultured leiomyoma cells but not in normal myometrial cells.	cdb	40-43	vascular endothelial growth factor B	Homo sapiens	106-112
16720624-7	2006	CONCLUSIONS: These results suggest that CDB-2914 down-regulates VEGF, ADM and their receptor contents and modulates PR isoform contents in cultured leiomyoma cells in a cell-type-specific manner.	cdb	40-43	vascular endothelial growth factor A	Homo sapiens	64-68
16720624-7	2006	CONCLUSIONS: These results suggest that CDB-2914 down-regulates VEGF, ADM and their receptor contents and modulates PR isoform contents in cultured leiomyoma cells in a cell-type-specific manner.	cdb	40-43	progesterone receptor	Homo sapiens	116-118
20414849-7	2010	Asoprisnil and/or CDB-2914 modulated the ratio of progesterone receptor isoforms (PR-A and PR-B) in cultured leiomyoma cells; decreased the cell viability; suppressed the expression of growth factors, angiogenic factors, and their receptors in those cells; and induced apoptosis through activating the mitochondrial and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) pathways and eliciting endoplasmic reticulum stress.	cdb	18-21	S100 calcium binding protein A6	Homo sapiens	82-86
20414849-7	2010	Asoprisnil and/or CDB-2914 modulated the ratio of progesterone receptor isoforms (PR-A and PR-B) in cultured leiomyoma cells; decreased the cell viability; suppressed the expression of growth factors, angiogenic factors, and their receptors in those cells; and induced apoptosis through activating the mitochondrial and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) pathways and eliciting endoplasmic reticulum stress.	cdb	18-21	RB transcriptional corepressor 1	Homo sapiens	91-95
18562709-6	2008	A population of ITGAX(+) ITGAM(low) DCs lacking ITGB7 are restricted to the cDB.	cdb	76-79	integrin alpha X	Mus musculus	16-21
18562709-6	2008	A population of ITGAX(+) ITGAM(low) DCs lacking ITGB7 are restricted to the cDB.	cdb	76-79	integrin subunit alpha M	Homo sapiens	25-30
18562709-6	2008	A population of ITGAX(+) ITGAM(low) DCs lacking ITGB7 are restricted to the cDB.	cdb	76-79	integrin beta 7	Mus musculus	48-53
18778185-4	2008	The best-known selective progesterone receptor modulators are mifepristone (RU 486), asoprisnil (J 867), onapristone (ZK 98299), ulipristal (CDB 2914), Proellex() (CDB 4124), ORG 33628 and ORG 31710.	cdb	141-144	progesterone receptor	Homo sapiens	25-46
18778185-4	2008	The best-known selective progesterone receptor modulators are mifepristone (RU 486), asoprisnil (J 867), onapristone (ZK 98299), ulipristal (CDB 2914), Proellex() (CDB 4124), ORG 33628 and ORG 31710.	cdb	164-167	progesterone receptor	Homo sapiens	25-46
17715432-4	2007	Consistent with the lower serum testosterone levels, pituitary Lhb and Fshb mRNA levels were increased 3.2- and 2.3-fold, respectively, by CDB-4022 treatment.	cdb	139-142	luteinizing hormone subunit beta	Rattus norvegicus	63-66
17715432-4	2007	Consistent with the lower serum testosterone levels, pituitary Lhb and Fshb mRNA levels were increased 3.2- and 2.3-fold, respectively, by CDB-4022 treatment.	cdb	139-142	follicle stimulating hormone subunit beta	Rattus norvegicus	71-75
16887885-5	2006	Prominent among the genes that were down-regulated in response to CDB-2914 was endothelin (ET)-2, a potent vasoactive molecule.	cdb	66-69	endothelin 2	Mus musculus	79-96
15572421-0	2005	Progesterone receptor modulator CDB-2914 down-regulates proliferative cell nuclear antigen and Bcl-2 protein expression and up-regulates caspase-3 and poly(adenosine 5"-diphosphate-ribose) polymerase expression in cultured human uterine leiomyoma cells.	cdb	32-35	caspase 3	Homo sapiens	137-146
15572421-7	2005	Compared with untreated control cultures, treatment with CDB-2914 decreased the number of viable cultured leiomyoma cells and the PCNA-positive rate in those cells and increased the TUNEL-positive rate in cultured leiomyoma cells in a dose-dependent manner.	cdb	57-60	proliferating cell nuclear antigen	Homo sapiens	130-134
15572421-8	2005	Western blot analysis revealed that treatment with CDB-2914 significantly decreased the expression of PCNA and Bcl-2 protein and increased the expression of cleaved caspase-3 and cleaved PARP in a dose-dependent manner compared with untreated control cultures.	cdb	51-54	proliferating cell nuclear antigen	Homo sapiens	102-106
15572421-8	2005	Western blot analysis revealed that treatment with CDB-2914 significantly decreased the expression of PCNA and Bcl-2 protein and increased the expression of cleaved caspase-3 and cleaved PARP in a dose-dependent manner compared with untreated control cultures.	cdb	51-54	BCL2 apoptosis regulator	Homo sapiens	111-116
15572421-8	2005	Western blot analysis revealed that treatment with CDB-2914 significantly decreased the expression of PCNA and Bcl-2 protein and increased the expression of cleaved caspase-3 and cleaved PARP in a dose-dependent manner compared with untreated control cultures.	cdb	51-54	caspase 3	Homo sapiens	165-174
15572421-8	2005	Western blot analysis revealed that treatment with CDB-2914 significantly decreased the expression of PCNA and Bcl-2 protein and increased the expression of cleaved caspase-3 and cleaved PARP in a dose-dependent manner compared with untreated control cultures.	cdb	51-54	poly(ADP-ribose) polymerase 1	Homo sapiens	187-191
1906396-6	1991	Many authors have investigated changes in the CD4+ (helper inducer) to subpopulations (1) made possible immunological monitoring following the organ CDB+ (cytotoxic suppressor) ratio following the organ transplant (2, 3, 4, 5).	cdb	149-152	CD4 molecule	Homo sapiens	46-49
14667993-2	2003	Its binding and antagonist potency with respect to the glucocorticoid receptor is significantly reduced compared to that of mifepristone, indicating that CDB(VA)-2914 belongs to a new class of dissociated progesterone receptor modulators that have reduced antiglucorticoid activity.	cdb	154-157	nuclear receptor subfamily 3 group C member 1	Homo sapiens	55-78
11771929-6	2001	Mean CdB was higher among children within 4 km of a zinc smelter and consuming > or =500 ml of tap water daily (x1.34; 95% CI=[1.14-1.51]) compared with children living more than 4 km away and consuming <500 ml of tap water daily.	cdb	5-8	nuclear RNA export factor 1	Homo sapiens	98-101
11771929-6	2001	Mean CdB was higher among children within 4 km of a zinc smelter and consuming > or =500 ml of tap water daily (x1.34; 95% CI=[1.14-1.51]) compared with children living more than 4 km away and consuming <500 ml of tap water daily.	cdb	5-8	nuclear RNA export factor 1	Homo sapiens	220-223
7601077-8	1995	Urinary RBP was found to be associated with PbB (partial r2 = 0.046, P = 0.005) in a stepwise regression analysis testing also the influence of age, sex, CdB, and ZPP.	cdb	154-157	retinol binding protein 4	Homo sapiens	8-11
11006215-1	2000	PURPOSE: Two mutations (R555Q and R124L) in the BIGH3 gene have been described in anterior or Bowman"s layer dystrophies (CDB).	cdb	122-125	transforming growth factor beta induced	Homo sapiens	48-53
30816207-5	2019	Alanine substitution of residues within the CDB of XRCC1 disrupt DNA binding in vitro and lead to a significant reduction in XRCC1 retention at DNA damage sites without affecting initial recruitment.	cdb	44-47	X-ray repair cross complementing 1	Homo sapiens	51-56
33082913-9	2020	The level of cadmium (CdB) was significantly higher in the L-Ca group than in the H-Ca group by 33%.	cdb	22-25	protein tyrosine phosphatase receptor type C	Homo sapiens	59-63
33132950-3	2020	This case report examines imitation and emotional availability in interaction between a mother and her 3-year-old child with CDB first in unguided play and then in three play sessions with tactile imitation guidance.	cdb	125-128	erb-b2 receptor tyrosine kinase 3	Homo sapiens	99-104
32783984-13	2020	CDB treatment significantly upregulated the expression of the mTOR, p-mTOR and p70S6K proteins and downregulated the expression of the Akt, p-Akt and p4EBP1 proteins.	cdb	0-3	mechanistic target of rapamycin kinase	Mus musculus	62-66
32783984-13	2020	CDB treatment significantly upregulated the expression of the mTOR, p-mTOR and p70S6K proteins and downregulated the expression of the Akt, p-Akt and p4EBP1 proteins.	cdb	0-3	mechanistic target of rapamycin kinase	Mus musculus	70-74
32783984-13	2020	CDB treatment significantly upregulated the expression of the mTOR, p-mTOR and p70S6K proteins and downregulated the expression of the Akt, p-Akt and p4EBP1 proteins.	cdb	0-3	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	79-85
32783984-13	2020	CDB treatment significantly upregulated the expression of the mTOR, p-mTOR and p70S6K proteins and downregulated the expression of the Akt, p-Akt and p4EBP1 proteins.	cdb	0-3	thymoma viral proto-oncogene 1	Mus musculus	135-138
32783984-13	2020	CDB treatment significantly upregulated the expression of the mTOR, p-mTOR and p70S6K proteins and downregulated the expression of the Akt, p-Akt and p4EBP1 proteins.	cdb	0-3	thymoma viral proto-oncogene 1	Mus musculus	142-145
32783984-15	2020	CONCLUSIONS: In conclusion, the dysfunction of the mTOR/ribosome pathway resulting in the inhibition of ribosome synthesis played an important role in the development of acute UC in mice, and CDB, but not RAPA, was an alternative drug for treatment of acute UC by enhancing ribosome synthesis via the mTOR/ribosome pathway and further promoting protein synthesis.	cdb	192-195	mechanistic target of rapamycin kinase	Mus musculus	51-55
32783984-15	2020	CONCLUSIONS: In conclusion, the dysfunction of the mTOR/ribosome pathway resulting in the inhibition of ribosome synthesis played an important role in the development of acute UC in mice, and CDB, but not RAPA, was an alternative drug for treatment of acute UC by enhancing ribosome synthesis via the mTOR/ribosome pathway and further promoting protein synthesis.	cdb	192-195	mechanistic target of rapamycin kinase	Mus musculus	301-305
30816207-5	2019	Alanine substitution of residues within the CDB of XRCC1 disrupt DNA binding in vitro and lead to a significant reduction in XRCC1 retention at DNA damage sites without affecting initial recruitment.	cdb	44-47	X-ray repair cross complementing 1	Homo sapiens	125-130
29326360-4	2018	Here, GK1.5 cys-diabody (cDb), an antimouse CD4 antibody fragment derived from the GK1.5 hybridoma, was used as a PET probe for CD4+ T cells in the dextran sulfate sodium (DSS) mouse model of IBD.	cdb	25-28	kallikrein 1-related peptidase b1	Mus musculus	6-9
29326360-4	2018	Here, GK1.5 cys-diabody (cDb), an antimouse CD4 antibody fragment derived from the GK1.5 hybridoma, was used as a PET probe for CD4+ T cells in the dextran sulfate sodium (DSS) mouse model of IBD.	cdb	25-28	CD4 antigen	Mus musculus	44-47
29326360-4	2018	Here, GK1.5 cys-diabody (cDb), an antimouse CD4 antibody fragment derived from the GK1.5 hybridoma, was used as a PET probe for CD4+ T cells in the dextran sulfate sodium (DSS) mouse model of IBD.	cdb	25-28	kallikrein 1-related peptidase b1	Mus musculus	83-86
29326360-4	2018	Here, GK1.5 cys-diabody (cDb), an antimouse CD4 antibody fragment derived from the GK1.5 hybridoma, was used as a PET probe for CD4+ T cells in the dextran sulfate sodium (DSS) mouse model of IBD.	cdb	25-28	CD4 antigen	Mus musculus	128-131
29326360-7	2018	89Zr-labeled GK1.5 cDb was used to image distribution of CD4+ T cells in the abdominal region and lymphoid organs of mice with DSS-induced colitis.	cdb	19-22	kallikrein 1-related peptidase b1	Mus musculus	13-16
29326360-7	2018	89Zr-labeled GK1.5 cDb was used to image distribution of CD4+ T cells in the abdominal region and lymphoid organs of mice with DSS-induced colitis.	cdb	19-22	CD4 antigen	Mus musculus	57-60
29326360-12	2018	Increased uptake of 89Zr-maleimide-deferoxamine (malDFO)-GK1.5 cDb in the distal colon of colitic mice was visible in vivo in PET scans, and region-of-interest analysis of the distal colon confirmed increased activity in DSS mice.	cdb	63-66	kallikrein 1-related peptidase b1	Mus musculus	57-60
29326360-15	2018	Conclusion:89Zr-malDFO-GK1.5 cDb detected CD4+ T cells in the colons, ceca, and MLNs of colitic mice and may prove useful for further investigations of CD4+ T cells in preclinical models of IBD, with potential to guide development of antibody-based imaging in human IBD.	cdb	29-32	kallikrein 1-related peptidase b1	Mus musculus	23-26
29326360-15	2018	Conclusion:89Zr-malDFO-GK1.5 cDb detected CD4+ T cells in the colons, ceca, and MLNs of colitic mice and may prove useful for further investigations of CD4+ T cells in preclinical models of IBD, with potential to guide development of antibody-based imaging in human IBD.	cdb	29-32	CD4 antigen	Mus musculus	42-45
29326360-15	2018	Conclusion:89Zr-malDFO-GK1.5 cDb detected CD4+ T cells in the colons, ceca, and MLNs of colitic mice and may prove useful for further investigations of CD4+ T cells in preclinical models of IBD, with potential to guide development of antibody-based imaging in human IBD.	cdb	29-32	CD4 antigen	Mus musculus	152-155
29672291-10	2018	A history of CDB (OR 2.1, p = 0.0090) and chronic kidney disease (CKD; OR 2.3, p = 0.035) were risk factors, and bleeding point identification (OR 0.20, p = 0.0037) was a preventive factor for re-bleeding.	cdb	13-16	olfactory receptor family 6 subfamily B member 2	Homo sapiens	18-24
27966069-3	2017	GK1.5 cys-diabody (cDb), a previously developed anti-mouse CD4 antibody fragment, was tested at different doses to assess its effects on positron emission tomography (PET) imaging and CD4+ T cell viability, proliferation, CD4 expression, and function.	cdb	19-22	kallikrein 1-related peptidase b15, pseudogene	Mus musculus	0-5
27966069-7	2017	RESULTS: For immunoPET imaging, the lowest protein dose of 2 mug of 89Zr-labeled GK1.5 cDb resulted in significantly higher % injected dose/g in inguinal lymph nodes (ILN) and spleen compared to the 12-mug protein dose.	cdb	87-90	kallikrein 1-related peptidase b15, pseudogene	Mus musculus	81-86
27966069-8	2017	In vivo administration of GK1.5 cDb at the high dose of 40 mug caused a transient decrease in CD4 expression in spleen, blood, lymph nodes, and thymus, which recovered within 3 days postinjection; this effect was reduced, although not abrogated, when 2 mug was administered.	cdb	32-35	kallikrein 1-related peptidase b1	Mus musculus	26-29
27966069-8	2017	In vivo administration of GK1.5 cDb at the high dose of 40 mug caused a transient decrease in CD4 expression in spleen, blood, lymph nodes, and thymus, which recovered within 3 days postinjection; this effect was reduced, although not abrogated, when 2 mug was administered.	cdb	32-35	CD4 antigen	Mus musculus	94-97
27966069-9	2017	Proliferation was inhibited in vivo in ILN but not the spleen by injection of 40 mug GK1.5 cDb.	cdb	91-94	kallikrein 1-related peptidase b15, pseudogene	Mus musculus	85-90
27966069-10	2017	Concentrations of GK1.5 cDb in excess of 25 nM significantly inhibited CD4+ T cell proliferation and interferon-gamma production in vitro.	cdb	24-27	kallikrein 1-related peptidase b15, pseudogene	Mus musculus	18-23
27966069-10	2017	Concentrations of GK1.5 cDb in excess of 25 nM significantly inhibited CD4+ T cell proliferation and interferon-gamma production in vitro.	cdb	24-27	CD4 antigen	Mus musculus	71-74
27966069-10	2017	Concentrations of GK1.5 cDb in excess of 25 nM significantly inhibited CD4+ T cell proliferation and interferon-gamma production in vitro.	cdb	24-27	interferon gamma	Mus musculus	101-117
27966069-11	2017	Overall, using low-dose GK1.5 cDb minimized biological effects on CD4+ T cells.	cdb	30-33	kallikrein 1-related peptidase b15, pseudogene	Mus musculus	24-29
27966069-11	2017	Overall, using low-dose GK1.5 cDb minimized biological effects on CD4+ T cells.	cdb	30-33	CD4 antigen	Mus musculus	66-69
27966069-12	2017	CONCLUSIONS: Low-dose GK1.5 cDb yields high-contrast immunoPET images with minimal effects on T cell biology in vitro and in vivo and may be a useful tool for investigating CD4+ T cells in the context of preclinical disease models.	cdb	28-31	kallikrein 1-related peptidase b15, pseudogene	Mus musculus	22-27
27966069-12	2017	CONCLUSIONS: Low-dose GK1.5 cDb yields high-contrast immunoPET images with minimal effects on T cell biology in vitro and in vivo and may be a useful tool for investigating CD4+ T cells in the context of preclinical disease models.	cdb	28-31	CD4 antigen	Mus musculus	173-176
26573799-2	2016	In this study, we describe the generation of (89)Zr-desferrioxamine-labeled anti-CD8 cys-diabody ((89)Zr-malDFO-169 cDb) for noninvasive immuno-PET tracking of endogenous CD8(+) T cells.	cdb	116-119	CD8a molecule	Homo sapiens	81-84
26573799-2	2016	In this study, we describe the generation of (89)Zr-desferrioxamine-labeled anti-CD8 cys-diabody ((89)Zr-malDFO-169 cDb) for noninvasive immuno-PET tracking of endogenous CD8(+) T cells.	cdb	116-119	CD8a molecule	Homo sapiens	171-174
26490315-4	2016	EXPERIMENTAL DESIGN: An antibody fragment (cys-diabody, cDb) against prostate stem cell antigen (PSCA) was conjugated to a far-red fluorophore, Cy5.	cdb	56-59	prostate stem cell antigen	Mus musculus	97-101